Chemically modified tetracyclines selectively inhibit IL-6 expression in osteoblasts by decreasing mRNA stability

Area of Science:

• Bone Biology
• Molecular Pharmacology
• Cytokine Signaling

Background:

• Interleukin-6 (IL-6) drives osteoclast formation and bone destruction in inflammatory conditions.
• Tetracycline derivatives show therapeutic potential for metabolic bone diseases by modulating bone cell activity.
• Chemically modified tetracyclines (CMTs) previously inhibited IL-1 beta-induced IL-6 secretion in osteoblastic cells.

Purpose of the Study:

• To investigate the molecular mechanisms by which doxycycline analogs CMT-8 and CMT-5 affect IL-6 gene expression in murine osteoblasts.
• To determine if CMT-8 and CMT-5 impact IL-6 promoter activity or mRNA stability.
• To explore the signaling pathways involved in CMT-8's regulation of IL-6 expression.

Main Methods:

• Murine osteoblasts (MC3T3-E1 cells) were treated with IL-1 beta and either CMT-8 or CMT-5.
• Quantitative analysis of IL-6 mRNA levels and IL-6 promoter activity using reporter gene assays.
• Assessment of IL-6 mRNA stability and Western blot analysis of key kinase phosphorylation (p38, JNK, ERK).

Main Results:

• CMT-8 significantly decreased IL-6 mRNA levels by approximately 50% upon IL-1 beta stimulation, while CMT-5 had no effect.
• CMT-8 did not alter IL-6 promoter activity but decreased IL-6 mRNA stability.
• The effect of CMT-8 on IL-6 expression was dependent on de novo protein synthesis and did not involve p38, JNK, or ERK pathways.

Conclusions:

• CMT-8 inhibits IL-1 beta-induced IL-6 gene expression in osteoblasts at the post-transcriptional level by reducing IL-6 mRNA stability.
• These findings suggest a novel mechanism for CMT-8 in modulating inflammatory bone disease pathogenesis.
• CMT-8 represents a potential therapeutic agent for IL-6-mediated metabolic bone disorders.